when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

BRISTOL MYERS SQUIBB · news · pharmadog

← back to BRISTOL MYERS SQUIBB

News mentioning BRISTOL MYERS SQUIBB

305 stories

Jul 30, 26Chutes & Ladders—Legend CEO departs without successor in placefiercebiotech

Jul 30, 26J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6Bbiopharma dive

Jul 30, 26BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delaysbiospace

Jul 30, 26Takeda, Regeneron, Sanofi and Bristol Myers trim pipelinesendpoints

Jul 30, 26BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearfiercebiotech

Jul 30, 26Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beatfiercebiotech

Jul 30, 26Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOsfiercebiotech

Jul 30, 26Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storebiospace

Jul 30, 26J&J pays Sail $785M, charting course to possible in vivo CAR-T buyoutfiercebiotech

Jul 29, 26MapLight CEO on what investors missed in the biotech’s schizophrenia databiopharma dive

Jul 29, 26Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationfiercebiotech

Jul 28, 26FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcommbiospace

Jul 27, 26MapLight dives despite positive data for schizophrenia drugbiopharma dive

Jul 27, 26MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readoutbiospace

Jul 27, 26InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis testfiercebiotech

Jul 27, 26Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdlebiospace

Jul 27, 26Summit, Merck must navigate new regulatory terrain in China-first cancer landscapebiospace

Jul 25, 26Anthropic’s life science plans; Novartis CEO on China deals; and moreendpoints

Jul 24, 26Summit has less than a year of cash runway left as PD-1/VEGF verdict nearsbiospace

Jul 23, 26Scancell to go public after winning reverse merger bid for troubled Neuphoriafiercebiotech

Jul 23, 26Biopharma layoffs must double in H2 for 2026 to match 2025 cutsbiospace

Jul 22, 26Summit and Akeso sharpen case for ivonescimab with new Western databiospace

Jul 22, 26Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely onbiospace

Jul 22, 26AI data becomes sticking point in biopharma dealmakingbiospace

Jul 21, 26Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’biopharma dive

Jul 21, 26Is there an exodus underway at Epic?stat

Jul 21, 26Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assetsfiercebiotech

Jul 20, 26FDA still focused on lettuce supplier as source of parasite, despite faulty test resultstat

Jul 20, 26STAT+: Pharmalittle: We’re reading about a telehealth firm and patient safety, PBMs overcharging, and morestat

Jul 20, 26Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide makerbiopharma dive

← prevpage 8 of 11next →